Drug Trial Radar · NCT06910358
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Apr 4, 2025
Primary completion
Sep 8, 2026
Study completion Sep 8, 2026
Sponsor
- Lead sponsor
- Disc Medicine, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Participants will complete daily questionnaires and attend study visits for assessments.
Conditions
- Erythropoietic Protoporphyria (EPP)
- X-Linked Protoporphyria (XLP)
Interventions
PlaceboDrug
Oral dose, once a day for 24 weeks
DISC-1459Drug
Oral dose, once a day for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatmentTime frame: 24 weeks
- Percent change from baseline in whole-blood metal-free PPIX levels at 6 monthsTime frame: 24 weeks
- Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment periodTime frame: 24 weeks
Locations
27 sites in 12 countries. Site status is shown where the registry gives one.
Marvel Clinical Research
Huntington Beach, California
University of California San Francisco
San Francisco, California
University of Miami Miller School of Medicine
Miami, Florida
Massachusetts General Hospital
Boston, Massachusetts
MetroBoston Clinical Partners
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Mount Sinai Hospital
New York, New York
Wake Forest University
Winston-Salem, North Carolina
Remington-Davis Clinical Research
Columbus, Ohio
University of Texas Medical Branch
Galveston, Texas
University of Washington
Seattle, Washington
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
UZ Leuven
Leuven, Belgium
University of Alberta
Edmonton, Alberta, Canada
CHU de Nantes - Hôtel Dieu, Service de dermatologie
Nantes, France, France
Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard
Paris, France, France
Charité - Universitätsmedizin Berlin, Institute of Allergology
Berlin, Germany, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, Germany
Children's Health Ireland (CHI)
Dublin, Ireland
Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS
Roma, Italy
Erasmus MC
Rotterdam, The Netherlands, Netherlands
Hospital Clinic de Barcelona
Barcelona, Spain, Spain
Karolinska University Hospital
Stockholm, Sweden, Sweden
Photobiology Unit, Salford Royal Hospital
Salford, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, England, United Kingdom
Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside
Dundee, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.